Eric P. Lefkofsky Sells 187,655 Shares of Tempus AI, Inc. (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric P. Lefkofsky sold 187,655 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total transaction of $7,044,568.70. Following the sale, the chief executive officer now directly owns 9,557,283 shares of the company’s stock, valued at $358,780,403.82. The trade was a 1.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Tempus AI Stock Performance

NASDAQ TEM opened at $35.54 on Friday. The firm’s fifty day simple moving average is $51.70. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Institutional Trading of Tempus AI

Several hedge funds and other institutional investors have recently bought and sold shares of TEM. First Horizon Advisors Inc. purchased a new stake in Tempus AI during the third quarter worth $30,000. Sandia Investment Management LP purchased a new stake in shares of Tempus AI during the 2nd quarter worth about $136,000. Vestor Capital LLC acquired a new stake in shares of Tempus AI during the 3rd quarter valued at about $153,000. Stifel Financial Corp purchased a new position in shares of Tempus AI in the 3rd quarter valued at about $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in Tempus AI during the third quarter worth approximately $258,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on TEM. Bank of America increased their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a report on Friday, December 13th. Loop Capital increased their price target on Tempus AI from $48.00 to $57.00 and gave the company a “buy” rating in a research note on Tuesday, October 15th. Wolfe Research began coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Stifel Nicolaus lowered shares of Tempus AI from a “buy” rating to a “hold” rating and increased their price objective for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Finally, Guggenheim began coverage on shares of Tempus AI in a research report on Monday, December 9th. They set a “buy” rating and a $74.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $56.00.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.